Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed LaboratoryCybin Corp. Is A Best In Class Psychedelics Company When Compared To Industry Bellwether Compass PathwaysMindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial AdvisorMind Medicine Inc. Launches First Of Its Kind Clinical Trials Using Synergistic Psychedelic CompoundsNuminus Wellness Is Building A World Class Psychedelic Research OrganizationHAVN Life Sciences Is Off To A Great Start Out Of The GateMydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related AssetsNuminus Announces Closing of Oversubscribed $4.6 Million OfferingRritual™ Announces Suite of Premium Functional Mushroom and Adaptogenic ElixirsCEO Spotlight: Doug Drysdale of Cybin Corp.Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and ChAWAKN Life Sciences Launches Clinical Research Division with Prof. David Nutt & Dr. Ben Sessa Identifying Suitable Apotheca Systems Reveals AI Platform for Psychedelic Assisted PsychotherapyPsychedelics Company Havn Life Announces Commencement of Public Trading on the CSEAion Therapeutic Files Five Patents with the United States Patent and Trademark OfficeCybin Corp Announces Doug Drysdale as Chief Executive OfficerCompass Pathways Is Set To Take Psychedelics Mainstream With An IPO On The NasdaqNuminus Files Restated Financial ReportsMydecine Innovations Group Has Put Together A World Class Organization From A Human Capital PerspectiveMindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

Compass Pathways Is Set To Take Psychedelics Mainstream With An IPO On The Nasdaq

Sep 1, 2020 • 7:25 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

2020 has been a banner year for the psychedelic sector and we believe that the industry is in the early stages of a major growth cycle.

Last week, Compass Pathways announced a major milestone and filed to go public on the Nasdaq Global Market under the symbol CMPS. The leading psychedelic therapy company is a high-profile opportunity that is backed by tech billionaire Peter Thiel and lead investor Christian Angermayer.

When compared to its peers, we believe that Compass represents an advanced opportunity that is focused on developing psychedelic therapies for the treatment of mental illnesses such as depression. The company was founded almost four years ago and has been nothing short of an execution story. Compass plans to raise $100 million in the initial public offering (IPO) and plans to use the proceeds to advance its therapies through Food and Drug Administration (FDA) clinical trials.

In 2018, Compass announced that the FDA had granted it breakthrough therapy status, which expedited the development process and puts the company in a league of its own.

In the public offering filing, Compass said that early signals from academic studies that use formulations of psilocybin have shown that psilocybin therapy could improve outcomes for patients that suffer from depression. Although studies that were highlighted by Compass analyzed products that were not developed by it, we are favorable on the data that was highlighted from the study.

According to data from Crunchbase, Compass has raised more than $115 million since inception and has one of the strongest balance sheets when compared to other companies in the sector. Compass’s largest shareholder is psychedelic drug firm Atai Life Sciences AG, which is controlled by Angermayer, which has invested in several compounds that have been studied for treatment of mental illness and opioid addiction.

We are favorable on the relationship that Compass has with Atai and will monitor how both stories continue to evolve. Going forward, we expect Compass’ offering to generate significant interest and is an opportunity to be aware of.

If you are interested in learning more about Compass Pathways, please email to be added to our distribution list.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.